首页> 外文OA文献 >PHP291 Market Access and Reimbursement Options For Orphan Durg Hospital Only Medicines In Europe – One Size Fits All?

【2h】

PHP291 Market Access and Reimbursement Options For Orphan Durg Hospital Only Medicines In Europe – One Size Fits All?

机译：PHP 291仅适用于孤儿药医院的市场准入和报销选项欧洲唯一的药物–一种规格可以满足所有人的需求？

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Vosgerau S.; Paulus G.; Plantoer S.;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012) [J] . Wonder Michael, Chin Geoffrey Expert review of pharmacoeconomics & outcomes research . 2015,第5期

机译：“常规”经济评估对患者获得新的孤儿药物有什么影响？他们在澳大利亚的报销比较研究（2005-2012年）
2. Understanding the trends in international agreements on pricing and reimbursement for newly marketed medicines and their implications for access to medicines: a computational text analysis [J] . Kyung-Bok Son Globalization and Health . 2020,第1期

机译：了解新销售药物的定价和报销的国际协定趋势及其对药物获取的影响：计算文本分析
3. Patent-related barriers to market entry for generic medicines in the European Union: A review of weaknesses in the current European patent system and their impact on market access of generic medicines [J] . Kristof Roox, Julia Pike, Andrew Brown, Journal of generic medicines . 2008,第4期

机译：欧洲联盟普通药物市场进入的专利相关障碍：对当前欧洲专利制度的弱点及其对仿制药市场进入的影响
4. The European ESCO market: recent trends, market sizes, barriers and drivers and the remaining market potential [C] . Benigna Boza-Kiss, Paolo Bertoldi, Strahil Panev eceee summer study on energy efficiency;European Council for an Energy Efficient Economy . 2015

机译：欧洲ESCO市场：近期趋势，市场规模，障碍和驱动因素以及剩余的市场潜力
5. The economic behavior of for-profit and nonprofit hospitals: The impact of ownership on responses to changing reimbursement and market environments. [D] . Needleman, Jack. 1995

机译：营利性和非营利性医院的经济行为：所有权对对报销和市场环境变化的反应的影响。
6. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment [O] . Krzysztof Piotr Malinowski, Paweł Kawalec, Wojciech Trabka, 2018

机译：与欧洲药品管理局授权类型有关的欧洲孤儿药报销以及基于卫生技术评估的决策
7. PHP161 Reimbursement Trends and Evidence Requirements for Ultra-Orphan Therapies Across Europe: Optimising Market Access in Increasingly Challenging Markets [O] . Morawski J., Paul A., Ransom J.F., 2014

机译：欧洲范围内超孤儿疗法的PHP161偿还趋势和证据要求：在日益挑战的市场中优化市场准入
8. Change in Profitability and Financial Distress of Critical Access Hospitals from Loss of Cost-Based Reimbursement. [R] . Holmes, M., Pink, G. H. 2013

机译：关键准入医院的盈利能力和财务困境的变化，以免基于成本的报销。

PHP291 Market Access and Reimbursement Options For Orphan Durg Hospital Only Medicines In Europe – One Size Fits All?

著录项

引文网络

相似文献

相关主题

期刊订阅